897 related articles for article (PubMed ID: 15785956)
1. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET.
Tsamita CS; Golemi A; Egesta L; Castellucci P; Nanni C; Stefoni V; Grassetto G; Rubello D; Tani M; Zinzani PL; Fanti S
Nucl Med Commun; 2008 Aug; 29(8):705-10. PubMed ID: 18753823
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
Ambrosini V; Rubello D; Castellucci P; Nanni C; Farsad M; Zinzani P; Alavi A; Tehranipour N; Al-Nahhas A; Fanti S
Nucl Med Rev Cent East Eur; 2006; 9(1):37-40. PubMed ID: 16791802
[TBL] [Abstract][Full Text] [Related]
6. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma.
Alinari L; Castellucci P; Elstrom R; Ambrosini V; Stefoni V; Nanni C; Berkowitz A; Tani M; Farsad M; Franchi R; Fanti S; Zinzani PL
Leuk Lymphoma; 2006 Oct; 47(10):2096-101. PubMed ID: 17071482
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
[TBL] [Abstract][Full Text] [Related]
10. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma.
Crocchiolo R; Fallanca F; Giovacchini G; Ferreri AJ; Assanelli A; Verona C; Pescarollo A; Bregni M; Ponzoni M; Gianolli L; Fazio F; Ciceri F
Ann Hematol; 2009 Dec; 88(12):1229-36. PubMed ID: 19468730
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
[TBL] [Abstract][Full Text] [Related]
12. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation.
Castellucci P; Nanni C; Farsad M; Alinari L; Zinzani P; Stefoni V; Battista G; Valentini D; Pettinato C; Marengo M; Boschi S; Canini R; Baccarani M; Monetti N; Franchi R; Rampin L; Fanti S; Rubello D
Nucl Med Commun; 2005 Aug; 26(8):689-94. PubMed ID: 16000986
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
15. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
16. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.
Zinzani PL; Stefoni V; Tani M; Fanti S; Musuraca G; Castellucci P; Marchi E; Fina M; Ambrosini V; Pellegrini C; Alinari L; Derenzini E; Montini G; Broccoli A; Bacci F; Pileri S; Baccarani M
J Clin Oncol; 2009 Apr; 27(11):1781-7. PubMed ID: 19273712
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
Ömür Ö; Baran Y; Oral A; Ceylan Y
Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
[TBL] [Abstract][Full Text] [Related]
19. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
